

REFERENCES

- Abou-Zeid CA.; Rook GA .; Manikins DE., Bartlett JH., Osborn TW.,and Branny JM.(1987):** Effect of the method of preparation of Bacilli-Calmette-Guering (BCG) Vaccine on the Properties of four daughter strains,*J App. L Bacterial.*, 63 (s).
- Adebisi SA., Oluboyo PO. and Ocarina AB (2000):** Effect of drug induced hyperuricaemia on renal function in Nigerians with pulmonary tuberculosis *Sci.* 29:297-300.
- Alastair JJ., and Wood M (1993):** Treatment of multidrug – resistant tuberculosis the New England *Journal of Medicine* 429 : 784 -791.
- Alcaid FR., Alford RH ., and Anne H .(1998):** Antimycobacterial agents Pg.(320 – 3600. In Goodman and Gilman's pharmacological Basis of therapeutics , 9thed . MC. Grew . Hill . Inc. New York . U.S.A
- Alford RH. , Avaniss - Aghajani EK., and Arson KH. (2000):** Antimycobacterial agent Pg. (350-360) in Man dell GL., Douglas, RG., and Bennett (eds.) principles and practices of infectious Disease Churchill Livingstone In New York .
- American Thoracic Society (2002):** Short Course Chemotherapy in Pulmonary tuberculosis with Rifampin Versus Ethambutol *Lancet.*112 :727-732.
- American Thoracic Society, Centers for Disease Control and prevention (2002):** Treatment of tuberculosis infection in adult and children (14th edition). *Am. J. Respir. Crit care. Med*; 149 : 1359 – 1374.
- Attorri S., Dunbar S.; and Clarridge JE.(III) (2000):** Assessment of morphology for rapid presumptive identification

- Mycobacterium–tuberculosis. *J. Clin. Microbial.* 38 :1426 – 1429.
- Bajolet LM., Evans KD., Nakasome AS., and Della Maze LM. (2001):** Identification of Mycobacterium tuberculosis directly from primary cultures using acridinium ester. Labeled. *J. Clin, Microbial*, 30 : 2427 - 2431 .
- Bajolet O., Beignet I., Bras me L., Jaussard R., Grasset D., and Gentilini M . (2001):** Isolation of an unusual Mycobacterium species from an AIDS Patients with acute Lymphadenitis *J. Clin. Microbial.*, 39 : 2018 - 2020.
- Balis ME. , Delouse LP., Vernon AS., and Bur man WH. (1999):** Adverse. Effects of first line antituberculous drugs Drug Pg.23-56 . (Medline).
- Ballows AH., Haussler W J., and Hermann KL. (1999):** Manual clinical Microbiology, 5th (eds.) American Society for Microbiology Pg. (310 : 320).
- Balme ID., Borrow TZ., Grass PA and Barrel TT .(1999):** Ethambutol in original treatment of tuberculosis. *Am Res. Respir Dis* 109:548 - 553 (Medline).
- Banejee LG. and Acocella GL (2000):** Clinical pharmacokinetic of Isoniazid Clin Pharmacokinetic 12:108-127.
- Barbara RR., Cole ST., Berkley AD.(2003):** Drug-resistance in mycobacterium. *Eur, Respir .J.* 8 (Suppl. 20): 7015 - 7035.
- Bernard DT., BadmerTF., Gurnee AN., Schaefer KC., and Matter LC. (1995):** Screening of respiratory tract specimens. For the presence of Mycobacterium-Tuberculosis. *J.Clin. Microbial*, 32: 1483 - 1487.
- Bernard PM., Bernann PJ. , and Doreen MB.(2000):** Journal of Biological Chemistry 366, Quoted from Grange JM. (1998). The mycobacterium Pg.(73 – 101) in top Ely and Wilson's, principals of bacteriology, Virology and immunity, 8th

- edition, Parker MT., and Collier LH., Systemic Bacteriology Vol .12. Edward-Arnold. London .
- Birt, DJ and Grilling DJ. (2000):** Adverse effect of antituberculous Drugs . Drugs 23:56 - 74
- Blomberg B. and Fourier B .(2002):** Fixed dose combination drug for tuberculosis: Application in standardized treatment regimens Drug 200 Pg. (311-315) Clin. Pharmacology, therapy.
- Boom WH., Canady PH., Fulton SA., Gearing AJ., and Rojas KJ. (2003):** Human Immunity to mycobacterium tuberculosis: T-Cell and antigen Processing tuberculosis 83 : 98 – 106.
- Boyd JC. and Marr JJ. (1998):** Decreasing viability of acid-fast smears techniques for detection of tuberculosis. *Ann. Intern. Med.* 82 :489-492.
- Breman DJ.(2005):** Ultra structure of Mycobacterium tuberculosis Pg.(271-284) tuberculosis-Pathogenesis-protection, and Control, Asm. Press , Washington, DC.
- British Thoracic and Tuberculosis Association (1995):** Short Course chemotherapy in pulmonary tuberculosis: second report results during the 24 Month after the and chemotherapy *Am Rev. Respir. Dis.* 126 : 460-462 .
- Brooks GF., Marks J., and Szulgat CD .(1998):** A New Practical classification of Mycobacterium. *J. Medic. Microbial*, 9 : 253-258
- Brooks GF., Butler JS., and Morse SA (2000):** Medical Microbiology. Chapter 24:279-.288 (21 edition) by Appleton .Lang, U.K.
- Broth well DR. (2005):** Mortality and morbidity trends in tuberculosis. *J . Am . Rev . Respir. Dis.* 137:1217 -1220.
- Bur dash NM., Haros LM., Manos J P., and Ross DH. (1990):** Evaluation of the acid-fast smears. *J. Clin . Microbial* . 4 : 190 : 191.

- Butler AR., Allston CA., and Assault Ak .(2000):** The Jaffe reaction . identification of the Colored species. *Clin. Chime. Acta* 56 :227 -230.
- CDC, Core Curriculum on tuberculosis (2004):** What the clinician should know. Third ed. (c) National Center for preventive services. Division of tuberculosis. Elimination, Atlanta, G.A.
- CDC. Report (2000):** Reported tuberculosis in the United States. Short-Course Chemotherapy of pulmonary tuberculosis.
- Center for Disease Control and Prevention CDC. (1996):** USPH/ TDSA, guidelines for the prevention of opportunistic infection in persons infected with human-immunodeficiency virus-(Morbidity. Mort. Wkly, Res. 46 :1-46.
- Centers for Disease control and prevention (2002):** Essential components of tuberculosis preventive and control a program MMWR.,44:(RR-11):1-16 www.cdc.gov/nchstp/t6.
- Centers for Disease Control and prevention (2004):** Tuberculosis Morbidity-united states, 2004 Morbidity, Mortality, weekly Resp . 45: 365 -370 .
- Centers for disease Control and Prevention (CDC) (1999):** Biosafety in Microbiological and Biomedical laboratories. and 3rd edition. DHHS-publications NO . (CD), 43-8395. Department of Health and Human services public Health services.
- Central health laboratory Report ARE (2002):** Notes on the cultivation of tubercle bacilli and susceptibility drug test, the monthly bulletin of ministry of health ARE 35 :194 – 202.
- Chan XD.; Fan SW.; Hunter PJ.; Brennan BR.; and SR.; Bloom. (2005):** Infection and Immunity, *American Society for Microbiology* May (2005): 1722 - 1728
- Chung AJ., Todd JH., Sens AN., and Hazen - Martin JE. (2002):** Amino glycosides antibiotics alter the electrogenic transport

properties of phospholipids and cellular membrane of proximal tubule cells . *toxicol, Path.* 20 : 603 – 621.

Couthen GH., Poi AE., and Ten Dam HG. (2000): Annual Risk of tuberculosis infection Geneva WHO, Tuberculosis program, Publications WHO. TB / 88 - 154.

Daniel Tm., Bats FD., and Dow ness KA. (1994): History of tuberculosis. In "tuberculosis: pathogenesis, protection and control " Barry R , Bloom (editor) Washington) USA.

Daphne YE.; Chantal QO.; and Martha NG. (2003): Incidence of serious side effects from first line–antituberculous drugs among patients treated for Active tuberculosis *Am . J Respir. Crit .care Med .* Vol 169 Pg. (172 – 177).

Davis AJ.; and Weber AM. (1994): INH Pharmacokinetic a compressive review with clinical emphasis, 4th edition . Philadelphia: Lipinski Pg. (585- 590).

Davis AK.; Villainous ME.; Rezone EM.; Elcookm GS.; and Maximal RM (1997): Streptomycin preventive therapy for tuberculosis infection. *Am J. Respir Crit Care Med.* 155 : 1735 - 1738.

Dolin P J.; Raviglione MC.; and Koch AL.; (1993): Global tuberculosis incidence and Mortality during (1990-2005) *Bull., WHO*, 72 : 213 – 220.

Elias RY. (1999): Evaluation of different bacteriological methods and techniques used for the diagnosis of mycobacterial infection in Man MD. thesis (Bact.) Depart , Cairo, University.

ELlner AS.; Ellen JO.; Baron LG.; and Gilchrist MH. (1999): Manual of Clini-microbicology 8th edition, ASM. Pres, Washing -ton DC.

Friedens MC.; Conan DL.; Waggoner RF.; and McClatchy JK. (2002): Drug resistant tuberculosis : Review of the worldwide situation and Who /Ivatl D global Surveillance

- project *Clin. Infect. Dis.*, 24: 121 - 130.
- Gabye MH.; Pfeiffer FD.; and Richard JK. (2003):** Manual Clinical Microbiology 8th edition, ASM press, Washington, DC, Pg., (532-546).
- Gehane S A. (1994):** Differential identification of pathogenic mycobacteria isolated from patients Attending chest hospital thesis (MSC.Bact.) Suez Canal University.
- George MB. and Berlin HL.(1990):** Microscopy detection of and - fast bacilli clinical Microbiology 8th edition . 8: 222-228.
- George MB., Gordon FS.; and Maseur HM. (1999):** Journal of Applied Bacteriology 41:465 Quoted from Grange JM 1996. The Mycobacterium P (73-101) in : Topley and Wilson's Principles of Bacteriology, Virology and Immunity , 8th edition. Parker MT.; and Collier L.H (6.eds) Systemic Bacteriology . Vol 2. Parker MT.; and Doreen BL.; (eds.). Edwards, Arnold- London.
- Gilman LF., Strauss IH.; Earthwards DX. (1996):** Ethambutol. Absorption distribution and dosage in patient with renal tuberculosis chemotherapy 15: 148 - 157(Medline).
- Glickman MS. and Jacobs WR. (2001):** Microbial pathogenesis of mycobacterium tuberculosis 104: 477 - 485.
- Good R.; and Shin nick TM. (2000):** Mycobacterium, P.549-576 - In L. Collier, A. Bellows and Mossman (ed), Topley and Wilson's Microbiology and Microbial infections. Systematic Bacteriology, (9th edition) VOL.2 Edward, Arnold, London , U.K.
- Gordon M.; Churlish BV.;; Hawkins WE.; Watkins WG.; Sitar DS.; and Awoke FY.(2000):** Pharmacokinetics of Amino glycosides drugs in patients With tuberculosis. *Clin. Infect. Dis.* 25 : 104 – 111.
- Grange J.K and Collins C.H (1990):** Tubercle 64:141 in: Topley and Wilson's, Principles of Bacteriology, Virology and

- Immunity , 8th edition parker MT.; and Collier LH. (6.eds)
Systemic Bacteriology, Vol.2 , parker M.T.; Edward Arnold .
London .
- Grange JM. (1990):** Tuberculosis in Leslie-Collier Albert Balows
and Max sussman (EDS): Topely and Wilson's Microbiology
and Microbial infection 19th edition VOL.3,Pg.(397-404)
- Hageman L F.; Boyd and Marr J J .(1983):** Decreasing reliability
of acid-fast smear techniques for detection of tuberculosis.
Ann. Intern . Med . 82 : 389 –392.
- Hancek ML.; Cole ST. ;Combs DL.; and Dasios GK. (2000):** The
7H11 agar medium for the susceptibility test of
mycobacterium. *Am. Rev . Respir . Dis* , 98: 295 - 300
- Harrison's AM. (2002):** Principles of in Medicine (16th edition) part
6-infectious Disease section 8, Mycobacterium - infection
- Heifets LB.; and Good RC. (1999):** Current Laboratory methods for
the diagnosis of tuberculosis In: Bloom BR. (Eds.).
Tuberculosis: Pathogenesis, Protection, Identification and
Control. American Society for Microbiology , Washington .
DC.
- Heitage LM.; Taylor JG.; Smith PJ.; and McNairy BG. (2001):**
Excretion of Amino glycosides in patient with tuberculosis ,
AIDS and Diarrhea. *Clin. Infect. Dis*. 25 : 112 - 122 .
- Hermann L F.; David H L.; and Duet A L. (1999):** Probability
distribution of drug resistant Mutants in unselected
population of M . tuberculosis. *Appl . Microbiol*. 20 : 210 –
214.
- Hetherington HW.; and Wieshleman BF. (1958):** Pulmonary
tuberculosis-prevention and control "(C) by G.P, Putnam and
sons New York , USA.
- Heym LK.; Rid zone RN.; Meador JH.; Carson ML .;and Dutt
AK. (2000):** Antimicrobial agents and susceptibility tests:

- Mycobacteria In Murray PK.; Jordan RS. et al . (Eds.) Pg: 1385- 1391 Manual of Clinical Microbiology. American Society for Microbiology. Washington DC .
- Hishida NF.; Fillister PY.; Hat LR.; and Shahs LF. (2005):** Amino glycoside antibiotics induces rennin-angiotensin system and Local Vasoconstriction of Kidney proximal tubule. *Eur. J. Pharmacol.* 289 : 321 – 333.
- Hobby LJ.; Pine L F.; Boyter and Johnson MP .(1999):** Primary drug resistance: A continuing study of drug resistance in tuberculosis in veteran population within united states. *Am. Rev. respire Dis* .Pg(110- 113).
- Holtz HN and Lubing HN. (2000):** Peripheral neuropathy in tuberculosis patients treated with Isoniazid. *Am. Rev. Resp. Dis* .68: 458 . 461.
- Hong Kong Chest Service Tuberculosis Research Centre (MBMRC) (2004):** Double-blind placebo–controlled clinical trial of four ant tuberculosis chemoprophylaxis regimens in patients with pulmonary tuberculosis. *Am. Rev . Respir. Dis.* 145:36 – 41.
- Huener S.; Despvez RM.; and Heim CR. (2001):** Mycobacterium tuberculosis In: Man Dell GL.; Douglas RG.; and Bennett G. (Eds.) Principals and practice of infectious disease . 3rd ed . New York : Churchill Livingstone Pg.(1877-1880)
- Inderlied CB. (2001):** Antimycobacterial agents in vitro susceptibility testing, spectrums of activity, Mechanisms of action and resistance and assay for activity in biological fluids . In Lorain V. (Eds.) Antibiotics in Laboratory Medicine. *The Williams and Wilkins Co, Baltimore* , P g: (134 – 147) .
- Inderlied CB. ;and Sal finger MS. (2001):** Antimicrobial agents and susceptibility tests: Mycobacteria In Jordan E., Murray PR.; et al (Eds.) Pg. (1385 – 1394)_manual of Clinical

- Microbiology 5th Edition American Society for Microbiology, Washington DC.
- Jawtez AM.; Melini RC.; Adel berg 's Janet's Butyl; and Stephen A. Morse; (2005):** Medical Microbiology, (23rd edition) Boston Bur Ridge, New York, USA Pg., 140 - 149 .
- John LC.; Henry DC.; and Marry EA. (1999):** Drugs resistant mycobacteria tuberculosis in Korea isolates *Am. Rev. Respir. Dis.* 126 : 1092 – 1095.
- Joklik WK .; Willett HP.; Amos DB and Willard CM. (1990):** The Mycobacteria D. 423-488. In: *Zinsser Microbiology* , 10th edition . prentice . Hall . international . Inc
- Joklik SA.; Chaulet P.; Broth well DR. and Plikaytis BB. (2003):** Tuerculose et transition epidemilogique : *Le cas del'Algerie* . *Ann, Inst, Pasteur* . 4 : 181 – 187.
- Joklik Wk.; Willett H P.; Amos DB.; and Wilbert CM.(1990):** Medical Microbiology, (23rd edition) *Boston Bur Ridge ; New York , USA Pg., 140 – 149.*
- Kent PT.; and Kubica PG. (1985):** Public Heath Mycobacteriology a guide for the level (III) laboratory Centers for Disease Control 37-140.
- Kinyoun JJ. (1915):** A not on Uhlenhuth's method for sputum examination for tubercle bacilli. *Am .J. Pub . Health* 5 : 67-70.
- Klotman LC.; Vandeluele AN.; Boonville JP.; Kelley LP.; and Zhen G. (2002):** Amino glycosides incorporation along the nephron: auto radio- graphic study on isolated tubules. *Kidney int.* 14-259 –264.
- Kunnin GF.; Spiegel DM.; Malone RI. and Fish DN (2000):** Short Course-chemotherapy for tuberculosis with streptomycin :a controlled clinical study. *Tubercle* 61:41-44.
- Leitlmon DE.;and Weber WW. (2000):** Clinical Pharmacokinetics

- of Streptomycin. *Clin. Pharmacokinetic*. 4 : 451 - 462.
- Libonate LD.; Hacek D. and Raleigh J. (2000):** Modified proportion agar dilution test for slowly growing mycobacteria, clinical, microbial -Procedures. Handbook. *American Society for Microbiology , Washington DC*.
- Lip sky AL. ;and Marks J. (1990):** Notes on the cultivation of tubercle bacilli, *the monthly Bulletin of ministry of Health and public health lab. service* 19 : 194 - 202
- Luzzattoi JP.; Boehm JP.; Viler KW.; Snider DE. and Franks AL. (2002):** Effects of streptomycin on protein synthesis in patients treated with first line antituberculous drugs . *Am. Rev. Respi . Dis .* 19: 20-31.
- Man dell GL.; Douglas RG.; and Bennett (Eds.) (1996):** Principles and practices of infectious Disease, Antimycobacterial agents *Churchill Livingstone . Inc, New York*. P. 320-360.
- Man dell GL.; and Petri JR. (1999):** Drugs used in the chemotherapy of tuberculosis, *Mycobacterium Complex and leprosy- chapter 2*. p11s.1174.
- Martinez E.; Callao's J.; Mayor LM.; and Malone RS.; (2002):** Hypersensitivity reactions to rifampin. *Medicine (Baltimore)* 78,361-369(Gross Ref Medline)
- Mavromtidis K.; Magoula J.; and Taspa G. (2003):** Urate homeostasis in poly cystic kidney disease: comparison with chronic glomeruloneph . 24 : 447 - 59
- McCarran RO.; and Waits WE. (2000):** Purine metabolism and cell Physiology. jn recent. advances. In *Endocrinology and metabolism 1: 219-252.Ed.J.L.H Riordan,Edinburghi, Churchill, Livingstone, New York U.S.A*.
- Meyers JA.; Arthur AL. (1940):** "Man's Greatest Victory over tuberculosis "Pg. 199.201. By Charles .C.Thomas (editor) *Baltimore , MD, USA .*

- Mitchell Jr.; Zimmerman TJ.; Shake KG.; and Tumbrel KG. (2005):** INH liver injury. clinical spectrum pathology and probably pathogenesis. *Ann Intern, Med.* 24,181-196.
- Murray PR. (2001):** The acid-fast staining a specific and predictive test for my co bacterial disease. *Ann , Intern, med.*, 92:512-514.
- Nolan CM.; Goldberg SV. and Buskin SE.(1999):** Hepatotoxicity associated with Isoniazid preventive therapy JAMMA, 1999; 26; 1014-1018.
- Noordheek A C. ;and Wells AQ. (2000):** Typical tuberculosis lancet, I, 1221.
- Osha LS.;Richard LV.;MalisCD.; and Miller GH. (2001):** Specimen For Mycobacterial screening other than pulmonary specimen (1st edition) Pg.(33-36) New York, U.S.A.
- Patrick R.; Murray CA.; Michael A.; and Pfaller A. (2003):** Manual of Clini-Microbiology (2thed.) ASM, Washington.D.c, Pg.(50-81) USA.
- PDR Repot (1992):** Ethambutol-Isoniazid versus PAS-isoniazid in original treatment of pulmonary tuberculosis. *Am. Rev. Respir Dis .* 96:428-438.
- Petroff's SA. (1915):** A New and rapid method for the isolation and cultivation of tubercle bacilli directly From the sputum. *Exp. Med.*, 21:38-42.
- Pollock HM.; and Weiman EJ. (2000):** Smears results in the diagnosis of mycobacteriosis *J.Clin Microbiol*, 8 : 329-331.
- Rant man JM.; and March RH. (2000):** Adverse effects of antiluberculosis drugs make change in treatment tubercle. *J. Clin. Microb.* 2000 : 68 : 291 – 294.
- Reynolds LM.; Russell RW.; and Nakashima N. (1990):** Chemotherapy of tuberculosis-Charles C.Thomas, publisher Springfield (III)

- Rickman SW.; and Moyer's NP. (2000):** Increased sensitivity of acid-fast smears. *J. Clin, Microbiol* 20 : 618 – 620.
- Roberts EG.; Maynard D.; Cromwell B.; Courtier LM.; and Drug eon H. (1991):** Rapid identification of mycobacterial species *Resp. Microbiol.* p. 145 : (33-70).
- Russell JR.; Bennett SN.; Peterson DR.; Johnson WN.; Hall B.; Robinson-Dune RT.; and Dietrich S. (1996):** Bronchoscope associated. Mycobacterium tuberculosis Pseudo infection. *Am. J. Respir.Crit ,Care, Med.* 150 : 245 – 250.
- Russell JR.; Feldman WH.; Fries JW. and Wirth DF. (2000):** Chemotherapy of tuberculosis *Charles, C. Thomas. publisher Spring field IV.*
- Salfinger AL.; Aggie MB.; Weiss CK.; and Plorde LC. (1998)** Evaluation of four mycobacterial blood cultures media BACTEC 12B Isolator, BACTEC13A, Middle brook Agar and biphasic medium Diagnostic. *Microbiology Infect. Dis.* 12:303-308.
- Sandor M.; Weinstocks Jr.; Wayne TA.; and Kim KS. (2003):** Granulomas in mycobacterial infection a modal of local, immune response . *Trends. Immunology* , 24 : 1-44.
- Selva RL.; Eisenach KD.; Gifford MD.; and Bates JH. (2001):** Biological and pathogenic characteristic of M. Tuberculosis. *J.Clin.Microbiol* 44-: 241 - 260.
- Siddiqi ET.; Niles A.; Baiting AG.; Carlson GH. (2001):** Collaborative feasibility study of biphasic system (Roche-Septic –check ABF) for detection, isolation and susceptibility testing for mycobacteria. *J. Clin - Microbiol* 29:1719 - 1722.
- Smith LG. and Johnston RM. (1990):** The effect of repeated tuberculin testing on post–vaccination allergy. *Lancet* 5: 643

- 849.

- Smith LG.; Mohr JA. and Palmer CE. (1991):** High rate tuberculin conversion is Indochinese refuges. *JAMMA*, 248 – 2933.
- Sommers HM. (2002):** Laboratory diagnosis of mycobacteriosis Washington, D.C *American Society for Microbiology*.
- Springer LG.; Kilburn JO.; Hilbert LM.; and Cave MD. (2002):** Identification of Mycobacterium by Conventional tests. *J. Clin. Microbiol* 29 : 2468 - 2472 .
- Sriyabhaya N.; and Wongwatana CL. (2002):** Pulmonary infection caused by atypical mycobacteria. *Rev. Infect. Dis.* 5 : 1085 – 1087.
- Sydney M.; Lance R.; Ellen JO.; and Peterson MD. (1996):** Diagnostic Microbiology 9th edition Section (B) infectious disease, Mycobacterium. *Mosby, Philadelphia, New York, USA*. P (590-622).
- Takama TA.; Combs Gaiter LY.; and Franks Al. (1999):** Tuberculosis short-course chemo therapy trial 21 effectiveness and acceptability Report of the final results, *Ann Intern Med* 112:397 - 406.
- Telenti M.; daquiris JF.; Salvages M.; Santo Rionda MJ. and Men dozer MC. (2000):** Rifampin preventive therapy for tuberculosis infection. *Am . J. Respir, Crit Care Med.* 160:1739 – 1744.
- Tietz NW.; Fosston P.; Tamaoku K. and Brenham D. (1995):** Clinical Guide laboratory test 3rd edition *W.B. Saunders CO. Philadelphia , PA* .
- Tobeau G.; Laurent MB.; Curlier S.; Abide P.; Malayan JA.; and Tulken PM.; (2005):** Tissue repaired in kidney cortex after short treatment with amino-glycosides at low-doses: a comparative biochemical and morph metric study. *Lab . Invest.* 54 : 385 - 393.

- Truant M.; Christie AB.; Citron KM. and Champ man JS. (1962):** Infectious disease: Epidemiology and clinical practice. Fourth ed *Churchill Livingston , Edinburgh London New York* P. 258
- Tulkens PM.; mingeot-leclerq Brasseux R.; and Morin JP. (2002):** Conformational and biochemical analysis of interaction phospholipids-amino glycosides antibiotics in relation with their toxicity. In *Brasseux (ed) CRC press, Inc, Boca Raton , fla , U.K* P.63- 43
- Veronique LM.; Young WD.; Masons MT. and Lifer JR.; (2003):** Development of paper strip test for detection of nana production by Mycobacterium and Nitrate-reduction. *Apple Microbial* 20 : 934 - 945.
- Vienna Nero Vestal AL.; and Warren AM. (2001):** Family mycobacteriaceae, In : *Holt, JG, Smith, PH. A., (Eds.), 9th ed . Baltimore : William and Wilkins in press.*
- Vincent Frebault MT. (2001)** Identification of Mycobacterium From culture by using the HPLC, Pigmentation and Gene Probe system for *M. avium* and *M. Tuberculosis* complex. *J. Clin Microbial* 26 : 2120 .
- Wallace Glass Roth J.; O'Brien R.; and Jones LF.; (2003):** Diagnosis and treatment of disease Caused by typical mycobacterium *AM . Rev . Respi . Dis .* 142 : 140 - 153 .
- Wantanabe M.; Widen RP.; Bauman V. and Cheeks RS. (2005):** Drug -induced lysosomal changes. *Acta-patho-Jpn.* 28:867-879.
- Wayne SC.; Wilkins EG.; Griffiths RG. and Roberts CC. (1999):** Pulmonary tuberculosis due to Mycobacterium bovis. *Thorax*, 41 : 685 - 687 .
- Weinberg JM.; Vmezawa HU.; Dogging GG.; and Forman N. (2002):** The role of cell calcium overload in nephrotoxic renal - tubular cell - injury. *Am .J. Kidney Dis* : 8 : 284 – 241.

- Wilding WB.; Newman DJ.; Price CP. and Fiona LL. (2001):** Fundamentals of Clinical Chemistry 5th Ed. Bruits, C.A., and Ash wood E.R.,W.B,Saunnders(Eds .Philadelphia US.A 200:414
- Wolfgang K.; Hilda p.; Bernard AM.; and Denville AL. (2000):** In current topics in infection : Mycobacterial disease (E.DJ Phillips) Arnold , London (Oxford text Book of Medicine).
- Woods GL. (1998):** Mycobacteria . *In wood GL;. and Gutierrez YC. (Eds.)* Diagnostic pathology of infectious Disease .
- Woods GL.; Wayne LG.; Flambé TA.; and Hunt J.M. (1998):** Mycobacteria in clinical diagnosis and management by laboratory methods. 19th ed. Edited by *Johan Bernard Henry (Ed.)* WB. Saunders Company Philadelphia, Pennsylvania P 1194 - 1209.
- World Health Organization (WHO) (2004):** Global tuberculosis control. WHO Report www.who.int/gtb/publications.
- World Health Organization (WHO) (2004):** Tuberculosis the world health report WHO, Global tuberculosis Programmed. www.brown.edu/courses/bio
- World Health Organization (WHO) (2005):** Tuberculosis *Wkly Epidemiology . Rec.*, 69 : 77 – 80.
- Young DS.; Bertie QS.; and Brewer TF. (2000):** Effects of Drug on clinical laboratory tests 4th edition AACCC press
- Zierk MG.; Beck EH.; Allan WB.; Jenkins PK.; and Wong HY. (2002):** Adverse reactions To daily and intermittent rifampin regimens for pulmonary tuberculosis In Hong. Kong *BMJ*.2: 765-770(Medline).